Table 1.

Study characteristics of studies investigating the prognostic relevance of HPV-16

Author	Year	Country	Total number of patients	Mean age	Clinical stage	Treatment	Number of patients with HPV-16 positive	Number of patients with HPV-18 negative	Median DFS	Median PFS	Median OS
Yat Ming Lau	2015	Hong Kong, China	236	54.4	I-III	radiotherapy+/−chemotherapy	142	94	73.2% vs. 81.2%, HR: 1.54, 95% CI = 0.93–2.56	NA	71.6% vs. 81.7%, HR: 0.99, 95% CI = 0.64–1.55
Dong Hang	2017	China	306	48	I-IV	surgery alone, surgery plus adjunctive chemotherapy, radiotherapy or chemoradiotherapy, concurrent chemoradiotherapy, chemotherapy or radiotherapy only.	186	120	NA	NA	HR: 0.36, 95% CI = 0.18–0.74, P = 0.005
Mamiko Onuki	2018	Japan	137	49.2	I-IV	Surgery+radiotherapy	59	78	NA	NA	HR: 0.42, 95% CI = 0.15–1.04, P = 0.06
Byoung Hyuck Kim	2019	Korea	298	48	I-IV	radiotherapy	164	127	NA	77.6 vs. 57.7%, P = 0.022	HR: 0.558, 95% CI = 0.326–0.955, P = 0.033
Sun-Hye Yang	2014	Korea	116	NA	I-IIA	surgery	49	67	NA	HR: 1.33, 95% CI = 0.31–5.67, P = 0.70	Not significant
Rossana de Arau ´jo Cata ~o Zampronha	2013	Brazil	86	40	I	Surgery+radiotherapy	30	56	HR: 1.104, 95% CI = 0.243–5.007	NA	NA

HPV Human papillomavirus, DFS Disease free survival, HR Hazard ratio, CI Confidence interval, NA Not available, DFS Disease free survival, PFS Progression free survival, OS Overall survival